Literature DB >> 2464397

The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer.

T G Armitage1, E H Cooper, D W Newling, M R Robinson, I Appleyard.   

Abstract

Serum prostate specific antigen (PSA) levels were measured in 139 patients with benign prostatic hyperplasia (BPH) and in 88 patients with prostate cancer who were managed by deferred treatment. Acute urinary retention and large prostate glands tended to be associated with high PSA levels, but at levels greater than 10 ng/ml there was a significant risk of carcinoma being found on subsequent histological examination. The risk of progression of untreated prostate cancer was associated with levels of PSA greater than 20 ng/ml and with a high rate of change of PSA level. The value of measuring PSA in these patients is discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2464397     DOI: 10.1111/j.1464-410x.1988.tb04431.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  12 in total

1.  IMPORTANCE OF PROSTATIC SPECIFIC ANTIGEN (PSA) IN CLINICAL PRACTICE : OUR EXPERIENCE.

Authors:  G S Chopra; R K Bindal; S V Kotwal; R Rai; J R Bhardwaj
Journal:  Med J Armed Forces India       Date:  2017-06-26

2.  Relationship between prostate-specific antigen, prostate volume, retention volume and age in benign prostatic hypertrophy (BPH).

Authors:  S Dutkiewicz; A Witeska; K Stepień
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

3.  Immunophenotypic Characterization of Benign and Malignant Prostatic Lesions.

Authors:  R Lakhtakia; R Bharadwaj; V K Kumar; P Mandal; S K Nema
Journal:  Med J Armed Forces India       Date:  2011-07-21

4.  Effects of chronic bacterial prostatitis on prostate specific antigen levels total and free in patients with benign prostatic hyperplasia and prostate cancer.

Authors:  Mohammed Nizar G Battikhi; Hussein Ismail; Qusey Battikhi
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

5.  Serum PSA and age-specific reference ranges in patients with prostatism symptoms.

Authors:  S Resim; M Cek; Z G Gürbüz; A Fazlioğlu; T Caşkurlu; A R Uras; G Sevin
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

6.  Age-specific reference ranges for prostate specific antigen-total and free in patients with prostatitis symptoms and patients at risk.

Authors:  M N G Battikhi; I Hussein
Journal:  Int Urol Nephrol       Date:  2006-12-02       Impact factor: 2.370

7.  Does Rigid Cystoscopy Affect the Total Serum Prostate-Specific Antigen Levels?

Authors:  Iqbal Singh; Ravi Prasad; Vivek Agarwal; R L Tripathi
Journal:  Indian J Surg       Date:  2013-02-15       Impact factor: 0.656

Review 8.  Emerging PSA-based tests to improve screening.

Authors:  Richard J Bryant; Hans Lilja
Journal:  Urol Clin North Am       Date:  2014-02-26       Impact factor: 2.241

9.  Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.

Authors:  Petra Leidinger; Martin Hart; Christina Backes; Stefanie Rheinheimer; Bastian Keck; Bernd Wullich; Andreas Keller; Eckart Meese
Journal:  Tumour Biol       Date:  2016-01-29

10.  The value of prognostic factors in prostatic cancer.

Authors:  J Schubert; S Kowalik
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.